Compare AVNW & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | TRDA |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.2M | 268.6M |
| IPO Year | 2007 | 2021 |
| Metric | AVNW | TRDA |
|---|---|---|
| Price | $21.39 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $34.50 | $21.00 |
| AVG Volume (30 Days) | 124.7K | ★ 318.9K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $243,858,000.00 | $25,421,000.00 |
| Revenue This Year | $5.59 | $39.97 |
| Revenue Next Year | $7.03 | $50.80 |
| P/E Ratio | $72.93 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $13.92 | $5.02 |
| 52 Week High | $27.02 | $16.45 |
| Indicator | AVNW | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 51.42 |
| Support Level | $20.60 | $5.71 |
| Resistance Level | $22.59 | $7.95 |
| Average True Range (ATR) | 0.77 | 0.39 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 43.37 | 51.92 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.